- Home
- HURA
as 07-14-2025 4:00pm EST
Stocks
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | TAMPA |
| Market Cap: | 103.3M | IPO Year: | N/A |
| Target Price: | $11.50 | AVG Volume (30 days): | 475.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.80 - $10.49 | Next Earning Date: | 08-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -37.91% | Revenue Growth (next year): | 69.15% |
Latest TuHURA Biosciences Inc. Common Stock News
HURA Breaking Stock News: Dive into HURA Ticker-Specific Updates for Smart Investing
MT Newswires
20 days ago
TuHURA Biosciences Launches Phase 3 Study of Potential Cancer Immunotherapy Drug
PR Newswire
20 days ago
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
MT Newswires
21 days ago
TuHURA Biosciences Shareholders Approve Merger With Kineta; Shares Rise
PR Newswire
21 days ago
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
MT Newswires
21 days ago
Brookline Capital Initiates Coverage on TuHURA Biosciences With Buy Rating, $9 Price Target
MT Newswires
a month ago
TuHURA Says FDA Lifts Partial Hold on Skin Cancer Study
PR Newswire
a month ago
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
PR Newswire
a month ago
TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy
Compare HURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HURA TuHURA Biosciences Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.